In the last years, ELTD1 was found to be highly expressed in human gliomas, a very aggressive type of brain cancer, and treatments have been started using anti–ELTD1 polyclonal antibodies in glioma preclinical models, but with promiscuous pAb binding [25]. The gene discussed is ADGRL4; the disease is central nervous system cancer.